Panobinostat in myelofibrosis

Claire Harrison, MD of the Guy’s and St. Thomas Hospital in London, UK, talks about panobinostat (LBH589), commonly used for the treatment of multiple myeloma, which is now being assessed in myelofibrosis (MF). Panobinostat in combination with ruxolitinib, has been shown to be efficacious and safe for the treatment of myelofibrosis. Other important markers also demonstrated the promising effects of this combinations, such as a 35% reduction in spleen volume and early delivery of changes in bone marrow morphology.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, in Orlando, FL.

Share this video